Back to PFEView Full Landscape
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
14 competitors in Non-Small Cell Lung Cancer
REGNLibtayo
Phase 3MRKArm A: Pemetrexed Cisplatin
Phase 2SNYoxaliplatine / gemcitabine / Vinorelbine
Phase 2RHHBYerlotinib HCl
Phase 2BNTXBNT327
Phase 2Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA4/2/2019
Vizimpro
Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
